Source comparison
MOTS-c Mechanism Comparison: Research vs Commercial Claims
AMPK Activation Confirmed via Western blot showing Thr172 phosphorylation increase of 2.5–3× baseline in muscle tissue (Lee et al., 2015) No mechanism verification. Formulations assume oral bioavailability without published absorption data Research formulation
This comparison does not assign a generated winner or score.
- AMPK Activation
- Confirmed via Western blot showing Thr172 phosphorylation increase of 2.5–3× baseline in muscle tissue (Lee et al., 2015)
- No mechanism verification. Formulations assume oral bioavailability without published absorption data
- Research formulations use IV or IP injection with verified tissue uptake; oral MOTS-c faces enzymatic degradation in the GI tract
- Mitochondrial Biogenesis
- PGC-1α mRNA expression increased 180% after four weeks of MOTS-c at 15 mg/kg (Nature Communications, 2020)
- Claims based on animal data without human dosing equivalency
- Effective dose in mice (15 mg/kg) translates to ~1,050 mg for a 70 kg human. Far above typical commercial doses of 5–10 mg
- Glucose Uptake (Insulin-Independent)
- GLUT4 translocation observed in C2C12 myotubes treated with 10 μM MOTS-c; effect blocked by AMPK inhibitor compound C
- Marketed as 'metabolic support' without specifying GLUT4 pathway or insulin sensitivity testing
- Insulin-independent glucose uptake is the key therapeutic mechanism in insulin-resistant populations. Not a performance feature
- Endurance Performance Gain
- 230–300% increase in running distance to exhaustion in middle-aged and young mice; effect lost when AMPK blocked
- Performance claims based on animal studies with no adjustment for species differences in metabolism
- Rodent endurance models do not translate linearly to human performance; human trials remain absent
- Administration Route
- Intraperitoneal or intravenous injection in all published efficacy studies
- Oral capsules, sublingual, or transdermal patches with no pharmacokinetic validation
- Peptides face proteolytic degradation in the stomach; subcutaneous injection is the only validated route for MOTS-c tissue delivery